← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #790 OF 1,000 MOST-CITED

Record maintenance 1 year (except exempt OTC)

FDA cited this observation 19 times across 19 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs19
BY FISCAL YEAR
FY20261
FY20252
FY20247
FY20231
FY20224
FY20211
FY20181
FY20172

How FDA worded it — real examples

All records of control associated with a batch of drug product were not maintained at least one (1) year after the expiration date.

PTI Georgia, LLC · Royston, Georgia · Drugs · 2026-01-16

All records of production and control associated with a batch of drug product were not maintained at least one (1) year after the expiration date.

Alnylam Pharmaceuticals Inc. · Cambridge, Massachusetts · Drugs · 2025-02-25

All records of production and control associated with a batch of drug product were not maintained at least one (1) year after the expiration date.

Person & Covey Inc · Glendale, California · Drugs · 2025-02-06

All records of components associated with a batch of drug product were not maintained at least one (1) year after the expiration date.

EnviroServe Chemicals Inc. · Dunn, North Carolina · Drugs · 2024-09-17

All records of control, distribution and labeling associated with a batch of drug product were not maintained at least one (1) year after the expiration date.

Chara Biologics, Inc. · Chatsworth, California · Drugs · 2024-08-16

All records of production and control associated with a batch of drug product were not maintained at least one (1) year after the expiration date.

Gland Pharma Limited · Hyderabad · Drugs · 2024-07-25

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →